Investor Market Report:

Mitochondrial dysfunction — leaders showing “solid progress”

Prepared March 17, 2026

1) Executive summary

Mitochondrial dysfunction has matured from a broad “energy” narrative into several *investable* mechanistic lanes with late-stage assets. In our longevity-biotech dataset, 196 companies have at least one asset explicitly tied to mitochondrial mechanisms (by target system, mechanism, or indication). The late-stage set is much smaller and concentrates in a few repeatable strategies:

Most bankable mechanistic lanes (by late-stage presence + clarity):

1. Inner mitochondrial membrane / cardiolipin stabilization (platform-like; multi-indication)
2. Mitochondria-targeted redox modulation (defined mito-disease focus; BBB-capable in some cases)
3. Mitochondrial gene replacement for defined complex I defects (highest biological specificity)
4. Bioenergetic substrate switching (ketone metabolism) (clinical endpoints are tractable in CNS)

Shortlist (best “solid progress” signals = Phase 3/4 depth + coherent thesis):

- Stealth BioTherapeutics (cardiolipin / IMM) — Phase 4 + Phase 3 programs
- Mitotech S.A. (mitochondria-targeted antioxidant; SkQ1) — Phase 3 ophthalmology franchise
- Khondrion (redox distress modulation; sonlicromanol/KH176) — Phase 3 in MELAS/primary mito disease
- GenSight Biologics (mitochondrial gene therapy ND4; LHON) — Phase 3
- Clene Inc. (bioenergetics; NAD+/mitochondrial energy metabolism) — Phase 3 in ALS
- Cerecin (ketone metabolism / brain bioenergetics; tricaprilin) — Phase 3 in Alzheimer’s
- T3D Therapeutics (metabolic nuclear receptor control; PPAR δ/γ) — Phase 3 (mitochondrial-adjacent)

© Copyright First Longevity Limited. Content generated by this chatbot is subject to our contractual terms and may not be published, reproduced, or shared publicly without prior written permission. www.longevity.technology

2) Investment thesis: why mitochondria can work now

What changed: the category is increasingly defined by *actionable sub-biology* (membrane lipid biology, complex I genetics, redox systems, fuel switching) rather than generic "mitochondrial support." This matters because it improves:

- Patient selection (genetic forms, biomarkerable redox distress, tissue-specific manifestations)
- Endpoint feasibility (ophthalmology, LHON visual endpoints, ALS functional measures, AD cognition + metabolic markers)
- Portfolio logic (one mechanism → multiple indications, rather than one-off assets)

Core diligence frame (3 questions):

1. Is the mechanism directly mitochondrial (IMM/cardiolipin, complex I, mtROS/redox, mitophagy), or merely upstream metabolic signaling?
2. Is there a credible measurement strategy (functional endpoints + disease-relevant biomarkers)?
3. Does the team show repeatable execution (multiple staged programs, not scattered claims)?

---

3) Company briefs (leaders with "solid progress")

A) Stealth BioTherapeutics — cardiolipin / inner mitochondrial membrane stabilization

Stage signal (dataset): *Elamipretide* listed as Phase 4 (post-market) for Barth syndrome, plus Phase 3 programs (e.g., dry AMD; primary mitochondrial myopathy due to nDNA mutations) and additional earlier-stage assets.

Why it's compelling

- Platform-like: cardiolipin/IMM biology is a reusable lever across high-energy tissues (muscle, retina, heart).
- Depth: multiple indications implies operational competence and a de-risking mindset.

Key diligence questions

- What is the *current* regulatory/commercial status by geography/indication for the Phase 4 asset labeling in the dataset?
- For Phase 3 assets: what were the prespecified endpoints and the reproducibility of functional benefits?

© Copyright First Longevity Limited. Content generated by this chatbot is subject to our contractual terms and may not be published, reproduced, or shared publicly without prior written permission. www.longevity.technology

Primary risks

- Heterogeneous clinical outcomes across indications (common in mitochondrial medicine).
- Payer/reimbursement and real-world adoption variability if endpoints are functional/quality-of-life heavy.

B) Mitotech S.A. — mitochondria-targeted antioxidant (SkQ1)

Stage signal (dataset): *Visomitin (SkQ1 ophthalmic)* listed as Phase 3 across ophthalmic uses (dry eye; dry AMD; uveitis) with additional earlier pipeline.

Why it's compelling

- Therapeutic focus (ophthalmology) with measurable endpoints tends to outperform "systemic" mitochondrial claims.
- Repeatability: same core mitochondrial oxidative stress/cardiolipin peroxidation thesis across adjacent indications.

Key diligence questions

- Evidence that mitochondrial targeting adds benefit vs standard antioxidant approaches.
- Trial design quality (masking, placebo effects in dry eye, objective markers).

Primary risks

- Crowded ophthalmology markets; differentiation must be clinically obvious.
- Late-stage success may not translate outside eye indications.

C) Khondrion — redox distress modulation (sonlicromanol / KH176)

Stage signal (dataset): *Sonlicromanol (KH176)* listed as Phase 3 in MELAS spectrum / primary mitochondrial disease, plus Phase 2 programs (including pediatric movement disorders in mitochondrial disease and post-COVID symptoms).

Why it's compelling

- High-need, genetically anchored patient populations; clearer path to regulatory alignment.

© Copyright First Longevity Limited. Content generated by this chatbot is subject to our contractual terms and may not be published, reproduced, or shared publicly without prior written permission. www.longevity.technology

- Pipeline logic: start in primary mito disease → expand into secondary mitochondrial dysfunction states.

Key diligence questions

- Magnitude and consistency of functional endpoints in MELAS/mito disease populations.
- Biomarker strategy for “redox distress” that’s reproducible across sites.

Primary risks

- Small, heterogeneous populations can produce noisy outcomes.
- Expansion into broader indications can dilute focus and raise trial costs.

D) GenSight Biologics — mitochondrial gene therapy for ND4 (LHON)

Stage signal (dataset): *LUMEVOQ (lenadogene nolparvovec)* listed as Phase 3 for LHON (ND4 mutation / complex I).

Why it’s compelling

- Cleanest biology in the set: mutation-defined mitochondrial complex I defect → targeted gene delivery.
- Endpoint clarity: vision endpoints provide more direct signal than many systemic mito syndromes.

Key diligence questions

- Durability of effect and bilateral/contralateral response interpretation.
- Manufacturing consistency and scalability for commercial execution.

Primary risks

- Gene therapy regulatory scrutiny; long-term follow-up burdens.
- Commercial sizing limited to a rare disease unless platform expands.

E) Clene Inc. — mitochondrial energy metabolism / NAD+/redox support

Stage signal (dataset): *CNM-Au8* listed as Phase 3 in ALS, and Phase 2 in MS and Parkinson’s.

© Copyright First Longevity Limited. Content generated by this chatbot is subject to our contractual terms and may not be published, reproduced, or shared publicly without prior written permission. www.longevity.technology

Why it's compelling

- Clear flagship: ALS as lead indication with neurodegenerative adjacency map.
- Unifying hypothesis: catalytic support of bioenergetics (NADH→NAD+) and oxidative stress reduction.

Key diligence questions

- Confirmatory evidence that observed effects map to mitochondrial function (vs non-specific neuroprotection).
- Regulatory path in ALS and statistical powering assumptions.

Primary risks

- ALS is a high-failure indication; signal must be robust and clinically meaningful.
- Platform perception risk: novelty can cut both ways if mechanism is debated.

F) Cerecin — ketone metabolism / brain bioenergetics (tricaprilin)

Stage signal (dataset): *CER-0001 (tricaprilin)* listed as Phase 3 in Alzheimer's; Phase 2 programs in migraine and infantile spasms.

Why it's compelling

- Clinical tractability: fuel-switching is measurable (ketone utilization, metabolic markers).
- CNS focus aligns with brain energy deficit hypotheses.

Key diligence questions

- Patient stratification strategy (metabolic phenotype responders vs non-responders).
- Ability to show meaningful cognitive/functional outcomes beyond metabolic changes.

Primary risks

- Alzheimer's clinical endpoints are hard; metabolic improvements may not translate.
- Competitive landscape includes other metabolic interventions.

G) T3D Therapeutics — PPAR δ/γ agonism (mitochondrial-adjacent metabolic control)

© Copyright First Longevity Limited. Content generated by this chatbot is subject to our contractual terms and may not be published, reproduced, or shared publicly without prior written permission. www.longevity.technology

Stage signal (dataset): *T3D-959* listed as Phase 3 in Alzheimer's, with earlier-stage follow-ons.

Why it's compelling (with caveat)

- Late-stage execution; coherent metabolic regulation thesis.
- Less "direct-to-mitochondria" than cardiolipin/redox/gene therapy plays.

Key diligence questions

- Evidence that PPAR modulation delivers mitochondrial-relevant outcomes in humans.
- Differentiation vs other metabolic/anti-inflammatory AD strategies.

Primary risks

- Mechanistic distance from mitochondria could weaken category-specific differentiation.
- AD endpoint risk remains the gating factor.

---

4) Portfolio recommendations (how to underwrite this space)

If building a focused mito portfolio, overweight:

- Direct mitochondrial targets with late-stage assets (cardiolipin/IMM; mito gene defects; redox distress modulation).
- Indication-first execution models (ophthalmology, LHON, MELAS) before broad "aging" claims.

Structure: barbell

- Anchor (lower risk within category): Stealth BioTherapeutics, Khondrion, GenSight Biologics (clear mechanism + late-stage)
- Upside (higher uncertainty / higher optionality): Clene, Cerecin, Mitotech (depending on endpoint robustness and competitive context)

---

5) Next-step diligence package (what I can generate next)

Pick one:

1. A ranked scorecard (stage, mechanistic directness, indication focus, pipeline depth, funding strength) for the full Phase 3/4 set

© Copyright First Longevity Limited. Content generated by this chatbot is subject to our contractual terms and may not be published, reproduced, or shared publicly without prior written permission. www.longevity.technology

2. A one-slide-per-company IC appendix (asset summary + why now + key risks + diligence questions)
3. A term-sheet lens: what milestones to price (data readouts, regulatory events, partnering)

Which format do you want, and should “solid progress” be scored strictly by Phase 3/4, or do you want me to include select Phase 2 programs with exceptional mechanistic specificity?

This is the end of the sample report, as you will see from above, we can run deeper reports depending on your intelligence requirements.

Contact our team: master@longevity.technology

www.longevity.technology/data

© Copyright First Longevity Limited. Content generated by this chatbot is subject to our contractual terms and may not be published, reproduced, or shared publicly without prior written permission. www.longevity.technology